Greece · Delayed Price · Currency is EUR Lavipharm Statistics
Total Valuation
Lavipharm has a market cap or net worth of EUR 134.62 million. The enterprise value is 162.25 million.
| Market Cap | 134.62M |
| Enterprise Value | 162.25M |
Important Dates
The next estimated earnings date is Monday, November 17, 2025.
| Earnings Date | Nov 17, 2025 |
| Ex-Dividend Date | Jul 17, 2025 |
Share Statistics
Lavipharm has 168.69 million shares outstanding. The number of shares has decreased by -0.18% in one year.
| Current Share Class | 168.69M |
| Shares Outstanding | 168.69M |
| Shares Change (YoY) | -0.18% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 3.39% |
| Float | n/a |
Valuation Ratios
The trailing PE ratio is 68.97.
| PE Ratio | 68.97 |
| Forward PE | n/a |
| PS Ratio | 2.46 |
| PB Ratio | 2.40 |
| P/TBV Ratio | 10.69 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 95.74 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 15.74, with an EV/FCF ratio of -25.54.
| EV / Earnings | 41.98 |
| EV / Sales | 2.97 |
| EV / EBITDA | 15.74 |
| EV / EBIT | 30.29 |
| EV / FCF | -25.54 |
Financial Position
The company has a current ratio of 1.28, with a Debt / Equity ratio of 0.60.
| Current Ratio | 1.28 |
| Quick Ratio | 0.67 |
| Debt / Equity | 0.60 |
| Debt / EBITDA | 3.28 |
| Debt / FCF | -5.32 |
| Interest Coverage | 2.82 |
Financial Efficiency
Return on equity (ROE) is 3.65% and return on invested capital (ROIC) is 3.88%.
| Return on Equity (ROE) | 3.65% |
| Return on Assets (ROA) | 2.68% |
| Return on Invested Capital (ROIC) | 3.88% |
| Return on Capital Employed (ROCE) | 6.02% |
| Revenue Per Employee | 193,823 |
| Profits Per Employee | 13,706 |
| Employee Count | 299 |
| Asset Turnover | 0.44 |
| Inventory Turnover | 1.46 |
Taxes
In the past 12 months, Lavipharm has paid 1.48 million in taxes.
| Income Tax | 1.48M |
| Effective Tax Rate | 43.08% |
Stock Price Statistics
The stock price has increased by +2.31% in the last 52 weeks. The beta is 1.18, so Lavipharm's price volatility has been higher than the market average.
| Beta (5Y) | 1.18 |
| 52-Week Price Change | +2.31% |
| 50-Day Moving Average | 0.82 |
| 200-Day Moving Average | 0.81 |
| Relative Strength Index (RSI) | 45.44 |
| Average Volume (20 Days) | 262,105 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Lavipharm had revenue of EUR 54.66 million and earned 3.87 million in profits. Earnings per share was 0.02.
| Revenue | 54.66M |
| Gross Profit | 24.87M |
| Operating Income | 5.36M |
| Pretax Income | 3.44M |
| Net Income | 3.87M |
| EBITDA | 9.55M |
| EBIT | 5.36M |
| Earnings Per Share (EPS) | 0.02 |
Balance Sheet
The company has 6.17 million in cash and 33.81 million in debt, giving a net cash position of -27.64 million or -0.16 per share.
| Cash & Cash Equivalents | 6.17M |
| Total Debt | 33.81M |
| Net Cash | -27.64M |
| Net Cash Per Share | -0.16 |
| Equity (Book Value) | 56.08M |
| Book Value Per Share | 0.33 |
| Working Capital | 10.60M |
Cash Flow
In the last 12 months, operating cash flow was 1.41 million and capital expenditures -7.76 million, giving a free cash flow of -6.35 million.
| Operating Cash Flow | 1.41M |
| Capital Expenditures | -7.76M |
| Free Cash Flow | -6.35M |
| FCF Per Share | -0.04 |
Margins
Gross margin is 45.50%, with operating and profit margins of 9.80% and 7.07%.
| Gross Margin | 45.50% |
| Operating Margin | 9.80% |
| Pretax Margin | 6.29% |
| Profit Margin | 7.07% |
| EBITDA Margin | 17.46% |
| EBIT Margin | 9.80% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.02, which amounts to a dividend yield of 2.51%.
| Dividend Per Share | 0.02 |
| Dividend Yield | 2.51% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | 0.18% |
| Shareholder Yield | 2.68% |
| Earnings Yield | 2.87% |
| FCF Yield | -4.72% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on August 1, 2022. It was a reverse split with a ratio of 0.3333333333.
| Last Split Date | Aug 1, 2022 |
| Split Type | Reverse |
| Split Ratio | 0.3333333333 |
Scores
Lavipharm has an Altman Z-Score of 1.61 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.61 |
| Piotroski F-Score | 5 |